Overview
- Last Friday Temple founder Deepinder Goyal posted that his team discovered a new biomarker called Entropy that is readable from the temple region and shown as a live 1–250 score updating every second.
- Temple described two derived measures, Entropy Maxima for peak exertion and Entropy Minima for resting metabolic cost, and said the score responds to sleep, stress, meals, caffeine, cold exposure, meditation and exercise.
- The company published internal benchmarking claiming Entropy correlated with metabolic‑cart calorimetry at r = 0.93 across more than 100 cardio sessions while heart rate showed r = 0.55, which Temple presented as evidence the metric tracks metabolic cost more closely than heart rate.
- Several neurologists and doctors have flagged that Temple has not released methodology, raw data, device specifications or peer‑reviewed studies, and they say correlation in company tests alone does not establish a validated biomarker.
- Temple is accepting early‑access applications and says external international studies are underway and will be submitted for peer review, but the firm has not announced launch timing, pricing, supported devices or full technical documentation and regulators and clinicians will likely await independent validation before adoption.